A new study published in The Lancet Rheumatology has found that immunocompromised individuals who receive at least three doses of a COVID-19 vaccine have a high prevalence of antibodies against the spike protein of the virus.
The research analyzed the blood samples of 287 participants with autoimmune diseases or receiving immunosuppressive treatments, who had received at least three doses of a COVID-19 vaccine.
The study found that 96% of participants had developed antibodies against the spike protein of the virus, which is a higher rate than what has been observed in the general population after two doses of a vaccine.
The study also found that the level of antibodies varied depending on the type of immunosuppressive treatment received by the participants.
Those on rituximab, a drug used to treat autoimmune diseases, had lower antibody levels compared to those on other immunosuppressive treatments.
The study suggests that individuals on rituximab or similar drugs may require additional vaccine doses to achieve adequate protection against COVID-19.
The findings of this study provide important insights into the immune response of immunocompromised individuals to COVID-19 vaccines.
These individuals are at a higher risk of severe illness or death from COVID-19, and the development of effective vaccination strategies is critical to protect this vulnerable population.
Further research is needed to determine the optimal vaccination regimen for immunocompromised individuals, especially those on immunosuppressive treatments, to ensure maximum protection against COVID-19.